Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic‐specific antigen in the evaluation of bladder outlet obstruction

International Journal of Urology - Tập 13 Số 12 - Trang 1509-1513 - 2006
Kok Bin Lim1, Henry Sun Sien Ho1, Keong Tatt Foo1, Michael Yuet Chen Wong1, Stephanie Fook‐Chong2
1Department of Urology, and
2Department of Clinical Research, Singapore General Hospital, Singapore

Tóm tắt

Aim: The aims of this study were to define the relationship between intravesical prostatic protrusion (IPP), prostate‐specific antigen (PSA) and prostate volume (PV) and to determine which one of them is the best predictor of bladder outlet obstruction (BOO) due to benign prostatic enlargement.

Methods: A prospective study of 114 male patients older than 50 years examined between November 2001 and 2002 was performed. They were evaluated with digital rectal examination, International Prostate Symptoms Score, PSA, uroflowmetry, postvoid residual urine measurement, IPP and PV using transabdominal ultrasound scan. Statistical analysis included scatter plot with Spearman’s correlation coefficients and nominal logistic regression

Results: Prostate volume, IPP and PSA showed parallel correlation. Although all three indices had good correlation with BOO index, IPP was the best. The Spearman rho correlation coefficients were 0.314, 0.408 and 0.507 for PV, PSA and IPP, respectively. Using receiver‐operator characteristic curves, the areas under the curve for PV, PSA and IPP were 0.637, 0.703 and 0.772, respectively. The positive predictive values of PV, PSA and IPP were 65%, 68% and 72%, respectively. Using a nominal regression model, IPP remained the most significant independent index to determine BOO.

Conclusions: All three non‐invasive indices correlate with one another. The study showed that IPP is a better predictor for BOO than PSA or PV.

Từ khóa


Tài liệu tham khảo

ChatelainCH DenisL FooKT KhouryS McConnellJ(eds). 5th International Consultation on BPH.Health United Publications UK 2001;519–33.

AUA Practice Guidelines Committee., 2003, AUA guideline on management of benign prostatic hyperplasia 2003. Chapter 1: diagnosis and treatment recommendations, J. Urol., 170, 530, 10.1097/01.ju.0000078083.38675.79

10.1046/j.1464-410x.1999.00121.x

10.1016/S0022-5347(01)64054-0

10.1016/j.jhin.2004.03.025

10.1159/000020356

10.1016/S0301-5629(02)00545-8

10.1002/1520-6777(2000)19:5<585::AID-NAU5>3.0.CO;2-U

10.1046/j.1464-410X.2003.04088.x

10.1046/j.1442-2042.2002.00453.x

10.1002/(SICI)1520-6777(1997)16:1<1::AID-NAU1>3.0.CO;2-I

10.1097/00005392-199601000-00072

10.1097/00005392-200101000-00008

10.1016/S0022-5347(05)00038-8

10.1016/S0090-4295(01)01155-4

10.1159/000052475

10.1016/S0090-4295(99)00232-0

10.1016/S0090-4295(98)00655-4

10.1016/S0302-2838(03)00384-1

10.1016/S0090-4295(98)00654-2

10.1111/j.1464-410X.2004.05158.x

10.1097/01.ju.0000095474.86981.00